Meeting report from the 2nd International HIV Workshop on Management of Treatment-Experienced Patients: September 26-27 2002, San Diego, Calif., USA

Antiviral Therapy

Volumn 7, Issue SUPPL. 2, 2002, Pages

  Montaner, Julio ^a   Mellors, John ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PHYSICIAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; VIRUS LOAD; ANTIBIOTIC RESISTANCE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT FAILURE;

EID: 1842514078     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Gazzard B, Pozniak A, Arasteh K, Staszewski S, Rozenbaum W, Yeni Y, van't Klooster G, De Dier K, Peeters M, de Béthune MP, Graham N & Pauwels R. TMC125, A next-generation NNRTI, demonstrates high potency after seven days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance. 9th Annual Conference on Retroviruses & Opportunistic Infections (CROI), Seattle, Wash., USA, 24-28 February 2002. Abstract 4.
2. Haas D, Zala C, Schrader S, Thiry A, McGovern R & Schnittman S. Once-daily atazanavir plus saquinavir favorably affects total cholesterol (TC) and fasting triglyceride (TG) profiles in patients failing prior PI therapy (trial AI424-009, wk 24). 41st Internscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Chicago, Ill., USA, 16-19 December 2001. Abstract LB-16.
3. Henry K, Lalezari J, O'Hearn M, Trottier B, Montaner J, Piliero P, Walmsley S, Chung J, Fang L, Delehanty J & Salgo M. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. XIV International AIDS Conference, Barcelona, Spain, 7-12 July 2002. Abstract LbOr19B.
4. Clotet B, Lazzarin A, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Chung J, Fang L, Delehanty J & Salgo M. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in Europe and Australia. XIV International AIDS Conference, Barcelona, Spain, 7-12 July 2002. Abstract LbOr19A.
5. Lu J, Sista P, Cammack N & Kuritzkes D. Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide). Antiviral Therapy 2002; 7:S56. Abstract 67.
6. Green J, Salgo M & Delehanty J. Patient survey on injection of T-20: ease of use and impact on activities. XIV International AIDS Conference, Barcelona, Spain, 7-12 July 2002. Abstract TuPeB4480.
7. Castagna A, Danise A, Hasson H, Boeri E, Lazzarin A, Peeters M, Piscitelli S & Hoetelmans R. The normalized inhibitory quotient (NIQ) of lopinavir is predictive of viral load response over 48 weeks in a cohort of highly experienced HIV-1-infected individuals. 9th Annual Conference on Retroviruses & Opportunistic Infections (CROI), Seattle, Wash., USA, 24-28 February 2002. Abstract 128.
8. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM & Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133:21-30.
9. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi J-P & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association 2000; 283:229-234.
10. Hossain MM, Coull JJ, Drusano GL & Margolis DM. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Research 2002; 55:41-52.
11. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A & Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14(18):2857-2867.
12. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK & Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine 2001; 344:472-480.
13. 3 and HIV RNA >50 000 cp/ml (GIGHAART ANRS 097). XIV International AIDS Conference. July 7-12, 2002, Barcelona, Spain. Abstract WePeB5887.
14. Ruiz L, Ribera E, Bonjoch A, Martínez-Picado J, Díaz M, Romeu J, Marfil S, Negredo E, García-Prado J, Tural C, Puig T, Sirera G & Clotet B. Virological and immunological benefit of a salvage therapy that includes kaletra plus fortovase preceded or not by antiretroviral therapy interruption in advanced HIV-infected patients with multidrug resistance mutations (48 weeks follow-up). Antiviral Therapy 2002; 7:S126. Abstract 154.